Bicara Therapeutics ratios data for the quarter ended Jun 2026. These financial ratios cover 8 quarters of results from Sep 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|
| Efficiency | ||||||||
| Assets AverageAssets Avg. | 517.08M | 494.04M | 465.83M | 439.14M | 427.84M | 492.30M | 532.92M | |
| Valuation | ||||||||
| Price to EarningsP/E | -15.88 | -13.97 | -19.28 | -18.51 | -23.74 | -25.48 | -23.19 | -35.31 |
| Price to BookP/B | 0.54 | 0.60 | 1.55 | 1.16 | 2.14 | 2.37 | 2.54 | 4.18 |
| Enterprise Value | -243.15M | -196.96M | 248.41M | 70.22M | 572.16M | 537.79M | 763.98M | 1,460.24M |
| EV to EBIT | 11.79 | 7.39 | -5.94 | -2.19 | -14.07 | -13.08 | -12.68 | -24.36 |
| EV to EBITDA | 11.79 | 7.39 | -5.94 | -2.19 | -14.07 | -13.08 | -12.68 | -24.36 |
| Market Capitalization | 277.65M | 292.75M | 710.51M | 506.83M | 862.33M | 952.59M | 1,303.73M | 1,957.50M |
| Price to FCFP/FCF | -16.11 | -9.74 | -25.28 | -19.80 | -29.44 | -39.49 | -34.70 | -44.22 |
| EV to FCF | 14.11 | 6.55 | -8.84 | -2.74 | -19.53 | -22.29 | -20.34 | -32.99 |
| EV to CFO | 14.12 | 6.56 | -8.84 | -2.74 | -19.56 | -22.51 | -20.37 | -33.03 |
| Return Ratios | ||||||||
| Return on Capital Employed [ROCE]ROCE | -16.51% | -22.91% | -26.99% | -33.75% | -39.01% | -38.43% | -41.27% | |
| Return on Assets [ROA]ROA | -13.15% | -18.69% | -22.04% | -27.67% | -32.24% | -31.96% | -34.78% |